Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 19/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.81 |
| ▸ | ALPL | P05186 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24318052 | 0.95 | PPARG (0.75) | PPARGCYP3A4ALPL | |
| SCHEMBL24279265 | 0.93 | PPARG (0.72) | PPARGCYP3A4ALPL | |
| SCHEMBL22732150 | 0.93 | PPARG (0.79) | PPARGCYP3A4ALPL | |
| SCHEMBL22517721 | 0.93 | PPARG (0.71) | PPARGCYP3A4ALPL | |
| Int131 SCHEMBL30035369 | 0.90 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL634767 | 0.90 | PPARG (1.00) | PPARGCYP3A4 | |
| Int131 SCHEMBL29404335 | 0.90 | PPARG (1.00) | PPARGCYP3A4 | |
| SCHEMBL23258024 | 0.89 | PPARG (0.73) | PPARGCYP3A4ALPL | |
| Int131 SCHEMBL635008 | 0.89 | PPARG (0.98) | PPARGCYP3A4 | |
| SCHEMBL21391656 | 0.89 | PPARG (1.00) | PPARGCYP3A4ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240066020-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | ANKURA TRUST COMPANY, LLC | 2024-02-29 | — | — | US | disclosed |
| WO-2022051316-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A SGLT-2 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051319-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A DPP-4 INHIBITOR | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2022051318-A1 | FIXED DOSE COMBINATIONS OF CHS-131 AND A THYROID RECEPTOR BETA AGONIST | Coherus Biosciences, Inc. (US) | 2022-03-10 | — | — | WO | disclosed |
| WO-2021076616-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | Coherus Biosciences, Inc. (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2020243058-A1 | COMPOSITIONS AND METHODS TO TREAT CANCER | Coherus Biosciences, Inc. (US) | 2020-12-03 | — | — | WO | disclosed |
| WO-2018053040-A1 | TREATMENT OF MULTIPLE SCLEROSIS WITH CHS-131 | INTEKRIN THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
| US-20170273969-A1 | Antidiabetic Solid Pharmaceutical Compositions | INTEKRIN THERAPEUTICS, INC. | 2017-09-28 | — | — | US | disclosed |
| US-9675603-B2 | Solid pharmaceutical compositions of ppary modulator | INTEKRIN THERAPEUTICS, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160263098-A1 | METHODS FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE AND/OR LIPODYSTROPHY | Coherus Biosciences, Inc. | 2016-09-15 | — | — | US | disclosed |
| US-20130243865-A1 | Antidiabetic Solid Pharmaceutical Compositions | Intekrin Therapeutics, Inc., INC. (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130245024-A1 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity | LANFEAR DENNIS (US) | 2013-09-19 | — | — | US | disclosed |
| EP-1677797-B1 | SALTS AND POLYMORPHS OF A POTENT ANTIDIABETIC COMPOUND | AMGEN INC (US) | 2012-02-22 | — | — | EP | disclosed |
| US-8003665-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-20110034380-A1 | COMBINATION OF A SELECTIVE PPAR-GAMMA MODULATOR AND AN INCRETIN FOR THE TREATMENT OF DIABETES AND OBESITY | INTEKRIN THERAPEUTICS, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. | 2007-12-20 | — | — | US | disclosed |
| US-7223761-B2 | Salts and polymorphs of a potent antidiabetic compound | AMGEN INC. (US) | 2007-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273969-A1 | Antidiabetic Solid Pharmaceutical Compositions | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 222/4885ALPL 1232/4885 |
| US-20070293536-A1 | Salts and polymorphs of a potent antidiabetic compound | PPARD, PPARA, PPARG | PPARG 3/4885CYP3A4 539/4885ALPL 245/4885 |
| US-20110034380-A1 | COMBINATION OF A SELECTIVE PPAR-GAMMA MODULATOR AND AN INCRETIN FOR THE TREATMENT OF DIABETES AND OBESITY | GPR119, PPARG, GLP1R | PPARG 2/4885CYP3A4 2425/4885ALPL 1663/4885 |
| US-20130243865-A1 | Antidiabetic Solid Pharmaceutical Compositions | PPARG, PPARA, PPARD | PPARG 1/4885CYP3A4 248/4885ALPL 1933/4885 |
| US-20240066020-A1 | COMPOSITIONS AND METHODS TO TREAT NON-ALCOHOLIC FATTY LIVER DISEASES (NAFLD) | SLC5A2, SLC10A1, SLC5A1 | PPARG 159/4885CYP3A4 341/4885ALPL 355/4885 |
| US-20130245024-A1 | Combination of PPARy Agonist and a Dipeptidyl Peptidase-Inhibitor for the Treatment of Diabetes and Obesity | DPP4, DPP3, DPP7 | PPARG 8/4885CYP3A4 165/4885ALPL 474/4885 |
| US-20160263098-A1 | METHODS FOR THE TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE AND/OR LIPODYSTROPHY | LIPC, GPR119, FABP1 | PPARG 5/4885CYP3A4 1842/4885ALPL 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.